

BioSyent Inc.

Interim Unaudited Condensed Consolidated Financial Statements

For the three months ended March 31, 2026 and 2025

Expressed in Canadian Dollars

Corporate Office
Suite 402
2476 Argentia Road
Mississauga, Ontario, L5N 6M1
Canada
Telephone 905.206.0013
Facsimile 905.206.1413
Email: info@biosyent.com
Web: www.biosyent.com




Management's Responsibility For Financial Reporting

To the Shareholders of BioSyent Inc.:

Management has prepared the interim unaudited condensed consolidated financial statements for BioSyent Inc. (the “**Company**”) in accordance with National Instrument 51-102 – *Continuous Disclosure Obligations* released by the Canadian Securities Administration. The Company discloses that its auditors have not reviewed these interim unaudited condensed consolidated financial statements for the three months ended March 31, 2026 and 2025.

Robert March



Vice-President and Chief Financial Officer, BioSyent Inc.


May 14, 2026

BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Financial Position

(Expressed in Canadian Dollars)

	AS AT	March 31, 2026	December 31, 2025
ASSETS			
Cash and cash equivalents (Note 6)		\$ 6,649,492	\$ 21,794,686
Short term investments (Note 7)		4,250,590	6,857,137
Trade and other receivables (Note 8)		7,487,075	4,456,562
Inventory (Note 9)		11,291,008	6,416,204
Prepaid expenses and deposits		1,575,746	187,977
Derivative asset (Note 10)		5,553	-
Loans receivable - current (Note 12)		63,694	80,395
CURRENT ASSETS		31,323,158	39,792,961
Long term investments (Note 11)		3,293,957	3,293,957
Loans receivable - non current (Note 12)		61,799	61,799
Deferred tax asset		526,742	510,932
Property and equipment (Note 13)		1,708,020	982,737
Intangible assets (Note 14)		21,828,234	4,797,073
Goodwill (Note 5)		3,750,000	-
TOTAL NON CURRENT ASSETS		31,168,752	9,646,498
TOTAL ASSETS		\$ 62,491,910	\$ 49,439,459
LIABILITIES AND SHAREHOLDERS' EQUITY			
Short term debt (Note 15)		\$ 4,000,000	\$ -
Accounts payable and accrued liabilities		8,104,058	6,147,907
Income tax payable		1,273,121	405,458
Contract liability (Note 16)		123,429	106,287
Derivative liability (Note 10)		-	23,608
Lease liabilities - current (Note 17)		433,838	214,360
Contingent consideration liability (Note 5)		1,816,894	-
Customer advances		812,393	317,988
CURRENT LIABILITIES		16,563,733	7,215,608
Deferred tax liability		121,543	131,601
Lease liabilities - non current (Note 17)		813,195	626,744
TOTAL NON CURRENT LIABILITIES		934,738	758,345
Share capital (Note 18)		8,717,798	5,245,760
Contributed surplus		1,795,726	2,163,428
Cumulative translation adjustment		(145,455)	(184,667)
Retained earnings		34,625,370	34,240,985
TOTAL EQUITY		44,993,439	41,465,506
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		\$62,491,910	\$ 49,439,459
Contingencies (Note 21)			
Commitments (Note 22)			
Related party transactions (Note 23)			
Subsequent event (Note 28)			

APPROVED ON BEHALF OF THE BOARD



René Goehrum
DIRECTOR
May 14, 2026



Joseph Arcuri
DIRECTOR
May 14, 2026

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Comprehensive Income

(Expressed in Canadian Dollars)

	For the three months ended March 31,	
	2026	2025
Net revenues from contracts with customers <i>(Note 27)</i>	\$ 13,908,182	\$ 10,978,960
Cost of goods sold <i>(Notes 9, 19)</i>	3,739,946	2,641,768
Gross profit	10,168,236	8,337,192
Selling, general and administration expenses <i>(Note 19)</i>	7,018,111	5,346,728
Operating profit	3,150,125	2,990,464
Finance costs <i>(Notes 15, 17, 19)</i>	31,616	13,103
Finance income <i>(Note 19)</i>	(166,792)	(179,010)
NET INCOME BEFORE TAXES	3,285,301	3,156,371
Current income tax	965,629	810,212
Deferred tax expense (recovery)	(25,147)	26,226
NET INCOME AFTER TAXES	2,344,819	2,319,933
OTHER COMPREHENSIVE INCOME		
Currency translation gains (losses)	39,212	(671)
TOTAL COMPREHENSIVE INCOME	\$2,384,031	\$ 2,319,262
Basic weighted average number of shares outstanding <i>(Note 20)</i>	11,336,104	11,269,162
Basic earnings per share <i>(Note 20)</i>	\$0.207	\$ 0.206
Diluted weighted average number of shares outstanding <i>(Note 20)</i>	11,597,602	11,515,873
Diluted earnings per share <i>(Note 20)</i>	\$0.202	\$ 0.201

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Cash Flows

(Expressed in Canadian Dollars)

	For the three months ended March 31,	
	2026	2025
OPERATING ACTIVITIES		
Net income after taxes	\$2,344,819	\$ 2,319,933
Items not affecting cash:		
Depreciation - property and equipment (Notes 13, 19)	94,112	66,907
Amortization - intangible assets (Notes 14, 19)	394,849	144,276
Share-based payments (Note 18)	145,949	149,736
Change in derivative asset / liability (Note 10)	(39,645)	14,450
Net finance income (Note 19)	(135,176)	(165,907)
MSLP loan interest accrued (Note 12)	(1,040)	(2,026)
Deferred tax expense (recovery)	(25,147)	26,226
Expected credit losses (Notes 10, 19)	661	-
Net change in non-cash working capital items:		
Trade and other receivables	(1,553,201)	(3,467,863)
Inventory	742,002	50,844
Prepaid expenses and deposits	(570,450)	(282,683)
Accounts payable and accrued liabilities	115,751	757,373
Contract liability	17,142	(31,849)
Customer advances	382,976	(658,032)
Income tax payable	807,791	360,217
Cash provided by (used in) operating activities	2,721,393	(718,398)
INVESTING ACTIVITIES		
Acquisition of Oral Science Inc. (Note 5)	(22,157,872)	-
Additions to property and equipment (Note 13)	(27,582)	(19,900)
Additions to intangible assets (Note 14)	-	(68,457)
Decrease (increase) in short term investments (Note 7)	2,606,547	(2,620,347)
Decrease in long term investments (Note 11)	-	2,606,546
Interest received	232,918	1,127,044
MSLP loan repayments received (Note 12)	17,741	55,425
Cash provided by (used in) investing activities	(19,328,248)	1,080,311
FINANCING ACTIVITIES		
Proceeds on short term bank debt - Acquisition of Oral Science Inc. (Note 15)	8,000,000	-
Payments - short term bank debt - principal (Note 15)	(4,000,000)	-
Payments - short term bank debt - interest (Note 15)	(18,957)	-
Payments - lease liability principal (Note 17)	(69,428)	(47,513)
Payments - lease liability interest (Note 17)	(12,659)	(13,103)
Repurchase of common shares - NCIB (Note 18)	(1,401,000)	(215,000)
Purchase of RSU Plan Shares - held in Trust (Note 18)	-	(453,780)
Payments for employee withholding taxes - RSU settlements (Note 18)	(481,210)	(286,834)
Net dividends paid (Note 18)	(619,481)	(563,311)
Proceeds from stock options exercised (Note 18)	25,184	58,538
Cash provided by (used in) financing activities	1,422,449	(1,521,003)
Effect of foreign currency translation adjustment	39,212	(671)
DECREASE IN CASH AND CASH EQUIVALENTS	(15,145,194)	(1,159,761)
Cash and cash equivalents, beginning of period	21,794,686	12,113,376
CASH AND CASH EQUIVALENTS - END OF PERIOD	\$ 6,649,492	\$ 10,953,615
SUPPLEMENTARY DISCLOSURE:		
NET CHANGE IN CASH AND INVESTMENTS		
Cash, short term and long term investments, beginning of period	\$ 31,945,780	\$ 26,044,542
Increase (decrease) in short term investments	(2,606,547)	2,620,347
(Decrease) in long term investments	-	(2,606,546)
Decrease in cash and cash equivalents	(15,145,194)	(1,159,761)
CASH AND INVESTMENTS - END OF PERIOD	\$ 14,194,039	\$ 24,898,582
CASH PAID FOR TAXES	\$ (157,838)	\$ (449,996)

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Changes in Shareholders' Equity

(Expressed in Canadian Dollars)

	Share Capital	Contributed Surplus	Cumulative Translation Adjustment	Retained Earnings	Total Shareholders' Equity
Balance as of January 1, 2026	\$ 5,245,760	\$ 2,163,428	\$ (184,667)	\$ 34,240,985	\$ 41,465,506
Comprehensive Income for the period	-	-	39,212	2,344,819	2,384,031
Share consideration issued in acquisition of Oral Science Inc. (Note 5)	3,474,460	-	-	-	3,474,460
Common shares repurchased under Normal Course Issuer Bid (Note 18)	(71,718)	-	-	(1,329,282)	(1,401,000)
Effect of Share-based payments: RSU expense (Note 18)	-	145,949	-	-	145,949
Effect of Share-based payments: Net Release of shares from RSU Plan Trust upon RSU vesting (Note 18)	19,310	(500,520)	-	-	(481,210)
Effect of Share-based payments: Options exercised (Note 18)	49,986	(24,802)	-	-	25,184
Dividends paid (Note 18)	-	11,671	-	(631,152)	(619,481)
Balance as of March 31, 2026	\$8,717,798	\$ 1,795,726	\$ (145,455)	\$34,625,370	\$44,993,439

	Share Capital	Contributed Surplus	Cumulative Translation Adjustment	Retained Earnings	Total Shareholders' Equity
Balance as of January 1, 2025	\$ 5,306,450	\$ 2,139,278	\$ (171,554)	\$ 27,729,011	\$ 35,003,185
Comprehensive Income for the period	-	-	(671)	2,319,933	2,319,262
Common shares repurchased under Normal Course Issuer Bid (Note 18)	(9,263)	-	-	(205,737)	(215,000)
Common shares repurchased and held in RSU Plan Trust (Note 18)	(453,780)	-	-	-	(453,780)
Effect of Share-based payments: RSU Expense (Note 18)	-	149,736	-	-	149,736
Effect of Share-based payments: Net Release of shares from RSU Plan Trust upon RSU vesting (Note 18)	180,765	(467,599)	-	-	(286,834)
Effect of Share-based payments: Options exercised (Note 18)	115,065	(56,527)	-	-	58,538
Dividends paid (Note 18)	-	10,110	-	(573,421)	(563,311)
Balance as of March 31, 2025	\$ 5,139,237	\$ 1,774,998	\$ (172,225)	\$ 29,269,786	\$ 36,011,796

The accompanying notes are an integral part of these interim unaudited condensed consolidated financial statements.

1. General Information

BioSyent Inc. (“**BioSyent**” or the “**Company**”) is a publicly traded specialty healthcare products company which, through its wholly-owned subsidiaries, BioSyent Pharma Inc., Oral Science Inc., and BioSyent Pharma International Inc., acquires or licences and further develops pharmaceutical and oral health products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly-owned subsidiary of BioSyent, operates the Company’s legacy business marketing biologically and health friendly non-chemical insecticides. The Company’s wholly-owned subsidiary Oral Science Inc. (acquired on March 1, 2026) operates the Company’s oral health business, distributing specialized dental hygiene and oral health products to Canadian dental clinics and consumers. BioSyent’s common shares are listed for trading on the TSX Venture Exchange under the symbol “RX”.

The accompanying interim unaudited condensed consolidated financial statements (the “**Financial Statements**”) of BioSyent include the accounts of BioSyent Inc. and its wholly-owned subsidiaries: BioSyent Pharma Inc., BioSyent Pharma International Inc., BioSyent Pharma Europe B.V., Hedley Technologies Ltd., Hedley Technologies (USA) Inc., Oral Science Inc., Oral Science International Inc. and Oral Science, USA Inc.

The Company changed its name from “Hedley Technologies Inc.” to “BioSyent Inc.” on June 13, 2006 to reflect the Company’s forward focus on the pharmaceutical market. BioSyent Pharma was incorporated on April 6, 2006 under the Canada Business Corporations Act and commenced operations in 2006. Hedley Technologies Ltd. was incorporated on January 30, 1996 in the province of British Columbia, Canada. Hedley Technologies (USA) Inc. was incorporated on May 13, 1994 in the state of Washington, USA. BioSyent Pharma International Inc. was incorporated on April 18, 2016 in Barbados. BioSyent Pharma Europe B.V. was incorporated in the Netherlands on February 24, 2025. The Company acquired Oral Science Inc. and its wholly-owned subsidiaries Oral Science International Inc. and Oral Science, USA Inc. in a business combination on March 1, 2026 (see *Note 5*).

BioSyent’s principal place of business is located at 2476 Argenta Road, Suite 402, Mississauga, Ontario, Canada L5N 6M1.

These Financial Statements were approved by the Board of Directors on May 14, 2026.

2. Basis of Presentation

The principal accounting policies adopted in the preparation of these Financial Statements on a historical cost basis, with the exception of those financial assets and liabilities at fair value through profit or loss (“**FVTPL**”), are set out below. The policies have been consistently applied to all the periods presented.

Statement of Compliance

These Financial Statements are in compliance with International Accounting Standard 34, “Interim Financial Reporting” (“**IAS 34**”). Accordingly, certain information and disclosures normally included in annual financial statements prepared in accordance with IFRS® Accounting Standards (“**IFRS**”), as issued by the International Accounting Standards Board (“**IASB**”) have been omitted or condensed.

Since these Financial Statements do not include all disclosures required by IFRS for annual financial statements, they should be read in conjunction with the Company’s audited consolidated financial statements for the year ended December 31, 2025.

Basis of Consolidation

All inter-company transactions have been eliminated in these Financial Statements.

Functional and Presentation Currency

The presentation currency of these Financial Statements is the Canadian dollar (“**CAD**”). The functional currency of the Company and its subsidiaries, BioSyent Pharma, Oral Science Inc., Oral Science International Inc., and Hedley Technologies Ltd., is the Canadian dollar. The functional currency of Hedley USA, Oral Science, USA Inc., and BioSyent Pharma International Inc. is the U.S. dollar (“**USD**”). The functional currency of BioSyent Pharma Europe B.V. is the European Euro (“**EUR**”).

All financial information has been rounded to the nearest dollar except where otherwise indicated.

3. Summary of Material Accounting Policies

The accounting policies adopted in the preparation of these Financial Statements are consistent with those followed in the preparation of the Company’s consolidated financial statements for the year ended December 31, 2025, except for the adoption of the following accounting policy relevant to the current interim period:

Business Combinations

Business combinations are accounted for using the acquisition method when the acquired set of activities and assets meets the definition of a business and control is transferred to the Company.

In determining whether a particular set of activities and assets is a business, the Company assesses whether the set of assets and activities acquired includes, at a minimum, an input and substantive process and whether the acquired set has the ability to produce outputs.

The consideration transferred in the acquisition is generally measured at fair value at the date of acquisition, as are the identifiable net assets acquired. Acquisition-related costs are expensed as incurred. The excess of the consideration over the fair value of the net identifiable assets acquired is recorded as goodwill.

If the initial accounting for a business combination is incomplete by the end of the reporting period in which the combination occurs, the Company reports provisional amounts for items for which the accounting is incomplete. Those provisional amounts are adjusted during the measurement period or additional assets or liabilities are recognized, to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the amounts recognized as of that date. The measurement period is the period from the date of acquisition to the date that the Company obtains complete information about the facts and circumstances that existed as of the acquisition date and is subject to a maximum period of one year.

Accounting Pronouncements Issued but not yet Effective

IFRS 18, Presentation and Disclosure in Financial Statements

In April 2024, the IASB issued *IFRS 18, Presentation and Disclosure in Financial Statements*. *IFRS 18* replaces *IAS 1 Presentation of Financial Statements* and introduces new presentation requirements within the statement of income or loss, including specified totals and subtotals, disclosure of management-defined performance measures, which may include EBITDA (“Earnings Before Interest,

Taxes, Depreciation and Amortization”), and aggregation and disaggregation of financial information based on identified roles of the primary financial statements and the notes. This new standard is effective for reporting periods beginning on or after January 1, 2027 and is to be applied retrospectively. Earlier application is permitted. The Company is currently assessing the potential impact of adopting this standard.

The Effects of Changes in Foreign Exchange Rates (Amendments to IAS 21)

The IASB has issued amendments that clarify how companies should translate financial statements from a non-hyperinflationary currency into a hyperinflationary one. These narrow-scope amendments aim to improve the usefulness of the resulting information in a cost-effective manner.

The amendments to IAS 21 *The Effects of Changes in Foreign Exchange Rates* are effective for annual periods beginning on or after 1 January 2027. Earlier application is permitted. The Company does not expect the impact to be material to the Company’s current or future reporting periods.

4. Use of Estimates and Accounting Judgments by Management

There have been no material revisions to the nature and amount of changes in estimates of amounts reported in the Company’s consolidated financial statements for the period ended March 31, 2026.

5. Acquisition of Oral Science Inc.

On March 1, 2026, the Company acquired 100% of the issued and outstanding shares of Oral Science Inc., a privately-owned Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard, Quebec.

Pursuant to the terms of a Share Purchase Agreement (“SPA”) dated February 8, 2026, BioSyent Inc., through a wholly-owned acquisition corporation, 17706138 Canada Inc., completed the acquisition of Oral Science from the shareholders of Oral Science (the “Sellers”) in an arm’s length transaction. The aggregate purchase price was \$25,500,000, satisfied by: (i) a cash payment of \$22,500,000 to the Sellers of which \$200,000 was satisfied with the grant of 12,666 Restricted Share Units (“RSUs”) to certain Oral Science employees pursuant to BioSyent Inc.’s RSU Plan which will fully vest on the second anniversary of the grant date; and (ii) the issue of 234,192 BioSyent common shares (the “Consideration Shares”) to the Sellers at a deemed issue price of \$12.81 per share (\$3,000,000 in aggregate) with a fair value of \$3,474,460 as of the March 31, 2026 closing date. BioSyent Inc. paid to the Sellers additional cash consideration of \$2,008,646 on closing, representing the excess working capital of Oral Science above the \$6,298,888 working capital requirement pursuant to the SPA. The Sellers are also entitled to a contingent cash earn-out payment in 2027 based on the performance of the Oral Science business in 2025 and 2026 as well as contingent royalty payments until 2033 based on the future sales of one product up to a maximum value of \$6,000,000. Contingent consideration is estimated at \$1,816,894 at March 31, 2026. This transaction qualified as an “Expedited Acquisition” under TSXV Policy 5.3: Acquisitions and Dispositions of Non-Cash Assets.

In accordance with the Company’s accounting policies and *IFRS 3 – Business Combinations*, this transaction will be accounted for using the acquisition method as the acquired assets and activities meet the definition of a business and control of that business has been transferred to the Company. The Company is currently in the process of allocating the purchase consideration to the assets acquired and liabilities assumed for accounting purposes. The measurement period for this acquisition transaction shall not exceed one year from acquisition date. Accordingly, the accounting for this transaction, including measurement of the purchase consideration and the fair value of net assets acquired and liabilities assumed, have been only provisionally determined as at March 31, 2026. The following table summarizes the provisional fair value of consideration paid and contingent consideration payable on the acquisition date as well as the provisional allocation of the purchase price to the net assets acquired and liabilities assumed. Once the purchase price allocation has been finalized, the values of the provisional amounts may change. These changes may be material.

Purchase Consideration	Amount	Working Capital	Amount
Cash on closing	\$ 24,308,646	Cash	\$ 2,150,774
234,192 common shares (Note 18) - Fair Value at Transaction Date	3,474,460	Trade and other receivables	1,775,920
12,666 RSUs (Note 18)	200,000	Inventory	5,616,805
Estimated contingent consideration	1,816,894	Prepaid expenses and deposits	817,319
Total purchase consideration	\$29,800,000	Accounts payable and accrued liabilities	(1,871,499)
		Income tax payable	(59,872)
		Derivative liability	(10,484)
		Customer advances	(111,429)
		Net working capital acquired	\$ 8,307,534

Provisional Purchase Price Allocation	Amount
Working capital (see below)	\$ 8,307,534
Property and equipment (Note 13)	791,813
Intangible assets (Note 14)	17,426,010
Goodwill	3,750,000
Lease liability (Note 17)	(475,357)
Net assets acquired	\$29,800,000

6. Cash and Cash Equivalents

Cash and cash equivalents consist of the following:

	March 31, 2026	December 31, 2025
Cash on deposit in banks	\$6,141,354	\$20,285,548
Redeemable GICs	508,138	1,509,138
Total cash and cash equivalents	\$6,649,492	\$21,794,686

7. Short term Investments

Short term investments consist of the following:

	March 31, 2026	December 31, 2025
Non-redeemable GICs	\$4,250,590	\$6,857,137
Total short term investments	\$4,250,590	\$6,857,137

8. Trade and Other Receivables

Trade and other receivables is comprised of the following:

	March 31, 2026	December 31, 2025
Trade accounts receivable (Note 10)	\$6,815,544	\$3,733,176
Accrued interest receivable on GICs	590,496	659,944
Other receivables	81,035	63,442
Total trade and other receivables	\$7,487,075	\$4,456,562

9. Inventory

Inventory is comprised of the following:

	March 31, 2026	December 31, 2025
Raw and Packaging Materials	\$966,232	\$1,574,113
Finished Goods	10,324,776	4,842,091
Total inventory	\$11,291,008	\$6,416,204

Cost of Goods Sold consists of the following:

	Three months ended March 31,	
	2026	2025
Raw and Packaging Materials and Finished Goods	\$3,638,437	\$2,562,358
Freight	101,509	79,410
Total cost of goods sold	\$3,739,946	\$2,641,768

10. Financial Instruments and Financial Risk Management

Fair Value Measurement

Fair Value Estimation of Financial Instruments

The carrying value of the Company's cash and cash equivalents, short term and long term investments, trade and other receivables, loans receivable, and accounts payable and accrued liabilities approximate their fair values. The difference between the carrying value and the fair value of the loans receivable due to interest being charged at the prescribed rate (see *Note 12*) is insignificant for the year.

Risks

The Company is exposed to a variety of financial risks by virtue of its activities: market risk (including foreign exchange risk, interest rate risk, and credit risk) and liquidity risk. The overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on financial performance. Risk management is carried out under the policies described below. Management is charged with the responsibility of establishing controls and procedures to ensure that financial risks are mitigated with the approved policies.

➤ Foreign Exchange Options and Forwards:

The Company periodically enters into foreign exchange options with financial institutions with investment grade credit ratings to manage its foreign exchange risk on contracts denominated in U.S. dollars. Such options are classified as derivative financial instruments

and measured at fair value through profit and loss. As at March 31, 2026, the Company had entered into options to purchase up to a total of USD 800,000 to USD 1,600,000 (December 31, 2025 - USD 1,840,000 to USD 3,280,000) at an exchange rate expressed in CAD per USD of 1.3550 (December 31, 2025 - 1.3550 to 1.3795) which will be settled on various dates between April 2026 and December 2026 (December 31, 2025 - January 2026 and December 2026). The Company's right to buy USD 800,000 (December 31, 2025 - USD 1,840,000) on the respective settlement dates is subject to the spot exchange rate on the settlement dates being above a rate of 1.3550 CAD per USD (December 31, 2025 - within a range of 1.3550 to 1.4050 CAD per USD). The Company's obligation to buy USD 1,600,000 (December 31, 2025 - USD 3,280,000) on the respective settlement dates is subject to the spot exchange rate on the settlement dates being below a rate of 1.3550 CAD per USD (December 31, 2025 - below a range of 1.3300 to 1.3495 CAD per USD).

The fair value of foreign exchange options is estimated based on quoted values from financial institutions. The Company's foreign exchange options and forwards resulted in a derivative asset of \$5,553 as at March 31, 2026 (December 31, 2025 - derivative liability of \$23,608).

The following table illustrates the Company's investment in foreign exchange options and forwards that are measured at fair value through profit and loss:

March 31, 2026	Level 1	Level 2	Level 3
Foreign Exchange Options and Forwards	-	\$5,553	-

December 31, 2025	Level 1	Level 2	Level 3
Foreign Exchange Options	-	(\$23,608)	-

➤ Foreign Exchange Risk:

The Company currently earns revenue in Canadian dollars, U.S. dollars and Euros and incurs costs in Canadian dollars, U.S. dollars and Euros. Management monitors the foreign currency net liability position on an ongoing basis during the year and adjusts the total

net monetary liability balance accordingly. When it is appropriate to de-risk future foreign exchange transactions, the Company uses foreign exchange options and forward contracts to manage foreign exchange transaction exposure.

The following tables present foreign exchange sensitivity analyses for the assets and liabilities of the Company denominated in foreign currencies:

Foreign Exchange Sensitivity Analysis - USD

Description of Asset/(Liability)	March 31, 2026	December 31, 2025
	USD	USD
Cash and cash equivalents	330,697	1,801,101
Accounts receivable	3,765	46,535
Less: Accounts payable	(670,159)	(1,021,666)
Net Total	(335,697)	825,970
Foreign Exchange Rate CAD per USD at the end of the period	1.3939	1.3706

At March 31, 2026, if the U.S. dollar had been stronger or weaker by 10% against the Canadian dollar with all other variables held constant, comprehensive income would have been \$34,393 lower or higher on an after-tax basis, respectively (December 31, 2025 - \$83,207 higher or lower, respectively).

Foreign Exchange Sensitivity Analysis - EUR

Description of Asset/(Liability)	March 31, 2026	December 31, 2025
	EUR	EUR
Cash and cash equivalents	702,847	529,224
Accounts receivable	211,490	397,681
Less: Accounts payable	(168,775)	(346,795)
Less: Customer advances	(398,444)	(116,171)
Net Total	347,118	463,939
Foreign Exchange Rate CAD per EUR at the end of the period	1.6072	1.6089

At March 31, 2026, if the Euro had been stronger or weaker by 10% against the Canadian dollar with all other variables held constant, comprehensive income would have been \$41,005 higher or lower on an after-tax basis, respectively (December 31, 2025 - \$54,863 higher or lower, respectively).

➤ Interest Rate Risk:

Cash flow interest rate risk is the risk that the future cash flow of a financial instrument will fluctuate because of changes in interest rates. Some of the Company's cash and cash equivalents as at the date of the Company's Consolidated Statements of Financial Position are invested in redeemable guaranteed investment certificates (each, a "GIC"), which earn interest at fixed rates during their tenure. The Company's short-term and long-term investments consist of non-redeemable GICs which also earn interest at fixed rates during their tenure. These GICs have original maturities of 9 to 36 months.

The Company manages its interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct operations on a day-to-day basis. Fluctuations in market rates of interest when these GICs are renewed may have an impact on the Company's finance income for the year. The Company actively manages the tenor of its GIC investments in order to maximize interest income over the short-term and long-term while maintaining the liquidity necessary to meet its operating, investing, and financing needs.

➤ Credit Risk:

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations and arises principally from the Company's cash and cash equivalents, short term and long term investments, trade and other receivables, and loans receivable. The carrying amount of financial assets represents maximum credit exposure. As the Company invests in GICs with Canadian Chartered Banks, its credit risk on this account is negligible. The Company's loans receivable (*see Note 12*) are full recourse and secured by a pledge of common shares of the Company purchased by the Borrowers, who are key management personnel. Based on these factors, the Company considers the credit risk associated with these loans receivable to be low. There are no factors at the end of the year to indicate a significant increase in credit risk has occurred and there are no defaults on the loans receivable.

In assessing the credit risk of its trade accounts receivable, the Company considers historical default rates and payment patterns, the nature of its customer base, and forward-looking information including any anticipated changes to its customer base, credit terms, and pricing.

Trade Receivables

Aged Trade Accounts Receivable	March 31, 2026	December 31, 2025
Current	\$ 5,146,929	\$ 3,017,915
Past due 1-30 days	1,203,021	521,142
Past due 31-60 days	228,593	144,382
Over 60 days	419,147	237,889
Expected Credit Losses	(182,146)	(188,152)
Closing Balance (Note 8)	\$ 6,815,544	\$ 3,733,176
Maximum Credit Risk	6,997,688	3,921,328

The Company has provided for expected credit losses of \$182,146 (December 31, 2025 - \$188,152) related primarily to disputed deductions on trade receivables adjusted for forward looking factors specific to certain Canadian pharmaceutical wholesale customers.

As of March 31, 2026, one customer represents 32% of net trade receivables (December 31, 2025 - 40%) while another customer represents 14% of net trade receivables (December 31, 2025 - 13%), a third customer represents 10% of net trade receivables (December 31, 2025 - 15%), and a fourth customer represents 7% of net trade receivables (December 31, 2025 - 12%).

Cash, cash equivalents, short-term investments and long-term investments are maintained with Canadian financial institutions and the wholly owned subsidiaries of these financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, subject to certain conditions, and are maintained with Canadian financial institutions of reputable credit and therefore bear minimal credit risk.

➤ Liquidity Risk:

Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. Senior management is actively involved in the review and approval of planned expenditures. All contractual maturities of accounts payable and accrued liabilities are due within one year. The Company has no other financial liabilities where the carrying value does not approximate fair value.

The Company generates sufficient cash from operating activities to fund its operations and fulfill its obligations as they become due. At March 31, 2026, the Company had credit facilities available with Royal Bank of Canada including a term loan facility and a revolving demand credit facility of up to \$12,000,000 (see Note 15), a foreign exchange facility, and credit card facilities totalling \$200,000.

11. Long term Investments

	March 31, 2026	December 31, 2025
Non-redeemable GICs	\$3,293,957	\$3,293,957
Total long term investments	\$3,293,957	\$3,293,957

12. Loans Receivable

On December 8, 2016, the Board of Directors approved a Management Share Loan Program (“MSLP”) under which the Company offered secured loans to certain management personnel employed by the Company (each a “Borrower”) up to a maximum of fifty percent of each Borrower’s base annual salary for the sole purpose of their purchase of the Company’s issued and outstanding common shares at prevailing market prices through the facilities of the TSX Venture Exchange.

	Loans Receivable (\$)
Balance, December 31, 2024	228,573
Repayments	(91,997)
Accrued Interest	5,618
Balance, December 31, 2025	142,194
Repayments	(17,741)
Accrued Interest	1,040
Balance, March 31, 2026	125,493
Current portion, March 31, 2026	63,694
Non-current portion, March 31, 2026	61,799
Current portion, December 31, 2025	80,395
Non-current portion, December 31, 2025	61,799

All common shares of the Company purchased with the proceeds of a loan are required to be pledged as security for the satisfaction and performance of the loan obligations. If the Borrower ceases to be employed by the Company or a subsidiary of the Company prior to the end of the original maturity dates or the extended maturity date, as applicable, all outstanding loan obligations shall become due and payable on the thirtieth (30th) day following the date of termination. In addition, in the event of a default by the Borrower of the terms of the loan, the loan obligations will become due and payable immediately.

Subject to the pledge on the common shares in favour of the Company, the Borrower is the sole owner of all common shares purchased on its behalf pursuant to the MSLP. All proceeds from the sale of common shares acquired through the MSLP are expected to be directed to the Company until the loan obligations have been satisfied in full.

As the loans are full recourse loans, they have not been accounted for as stock-based compensation, but as financial instruments within the scope of IFRS 9, Financial Instruments.

13. Property and Equipment

	Furniture and Fixtures	Equipment	Computer Equipment	Computer Software	Right-of-Use Asset (see Note 17)	Leasehold Improvements	Total
COST:							
December 31, 2024	\$ 268,303	\$ 266,367	\$ 411,868	\$ 408,382	\$ 1,330,455	\$ 680,511	\$ 3,365,886
2025 Additions	6,720	9,650	23,299	14,375	-	-	54,044
December 31, 2025	\$ 275,023	\$ 276,017	\$ 435,167	\$ 422,757	\$ 1,330,455	\$ 680,511	\$ 3,419,930
2026 Additions	9,032	-	18,550	-	-	-	27,582
Property and equipment acquired in acquisition of Oral Science Inc. (Note 5)	8,762	210,924	53,219	-	475,357	43,551	791,813
March 31, 2026	\$ 292,817	\$ 486,941	\$ 506,936	\$ 422,757	\$ 1,805,812	\$ 724,062	\$ 4,239,325
ACCUMULATED DEPRECIATION:							
December 31, 2024	\$ (200,742)	\$ (190,304)	\$ (330,540)	\$ (371,117)	\$ (709,578)	\$ (362,613)	\$ (2,164,894)
Changes in 2025	(12,643)	(17,328)	(27,894)	(13,336)	(133,046)	(68,052)	(272,299)
December 31, 2025	\$ (213,385)	\$ (207,632)	\$ (358,434)	\$ (384,453)	\$ (842,624)	\$ (430,665)	\$ (2,437,193)
Changes in 2026	(3,171)	(9,287)	(8,461)	(2,655)	(52,276)	(18,262)	(94,112)
March 31, 2026	\$ (216,556)	\$ (216,919)	\$ (366,895)	\$ (387,108)	\$ (894,900)	\$ (448,927)	\$ (2,531,305)
CARRYING AMOUNT							
December 31, 2024	\$ 67,561	\$ 76,063	\$ 81,328	\$ 37,265	\$ 620,877	\$ 317,898	\$ 1,200,992
December 31, 2025	\$ 61,638	\$ 68,385	\$ 76,733	\$ 38,304	\$ 487,831	\$ 249,846	\$ 982,737
March 31, 2026	\$ 76,261	\$ 270,022	\$ 140,041	\$ 35,649	\$ 910,912	\$ 275,135	\$ 1,708,020

14. Intangible Assets

	New Product Dossier and Filing Costs	Product Licenses and Rights	New Product Development	Trademarks and Patents	Intangible Assets Acquired in Business Combination	Total
COST:						
December 31, 2024	\$ 982,040	\$ 4,994,820	\$ 259,490	\$ 102,614	\$ -	\$ 6,338,964
2025 Additions	250,469	81,655	3,640	-	-	335,764
December 31, 2025	\$ 1,232,509	\$ 5,076,475	\$ 263,130	\$ 102,614	\$ -	\$ 6,674,728
2026 Additions	-	-	-	-	-	-
Intangible assets acquired in acquisition of Oral Science Inc. (Note 5)					17,426,010	17,426,010
March 31, 2026	\$ 1,232,509	\$ 5,076,475	\$ 263,130	\$ 102,614	\$ 17,426,010	\$ 24,100,738
ACCUMULATED AMORTIZATION:						
December 31, 2024	\$ (608,571)	\$ (581,359)	\$ (56,610)	\$ (50,923)	\$ -	\$ (1,297,463)
Changes in 2025	(117,622)	(438,408)	(5,764)	(18,398)	-	(580,192)
December 31, 2025	\$ (726,193)	\$ (1,019,767)	\$ (62,374)	\$ (69,321)	\$ -	\$ (1,877,655)
Changes in 2026	(29,405)	(109,602)	(1,441)	(4,401)	(250,000)	(394,849)
March 31, 2026	\$ (755,598)	\$ (1,129,369)	\$ (63,815)	\$ (73,722)	(250,000)	\$ (2,272,504)
CARRYING AMOUNT						
December 31, 2024	\$ 373,469	\$ 4,413,461	\$ 202,880	\$ 51,691	\$ -	\$ 5,041,501
December 31, 2025	\$ 506,316	\$ 4,056,708	\$ 200,756	\$ 33,293	\$ -	\$ 4,797,073
March 31, 2026	\$ 476,911	\$ 3,947,106	\$ 199,315	\$ 28,892	\$ 17,176,010	\$ 21,828,234

15. Short term debt

In connection with the Company's acquisition of Oral Science Inc. (see Note 5), the Company entered into a 1-Year \$6,000,000 Senior Secured Demand Term Loan (the "Term Loan Facility") and a \$12,000,000 Senior Secured Demand Revolving Credit Line Facility (the "Revolving Credit Line Facility") with Royal Bank of Canada, with the total of the two facilities not to exceed \$12,000,000. The Company also increased its credit card facility to a maximum amount of \$200,000.

In connection with the acquisition of Oral Science Inc. on March 1, 2026, the Company drew \$6,000,000 on the Term Loan Facility and \$2,000,000 on the Revolving Credit Line Facility.

The Term Loan Facility bears interest at a variable rate equal to the Canadian Overnight Repo Rate Average ("CORRA") plus 1.20% per annum and the Revolving Credit Line Facility bears interest at a variable rate equal to the RBC Prime Rate plus 0.25%. The Term Loan has a maturity date of September 30, 2026 with three quarterly principal payments of \$2,000,000 plus interest due on March 31, 2026, June 30, 2026, and September 30, 2026. The Revolving Credit Line Facility is due on demand.

These credit facilities are secured by a General Security Agreement constituting a first ranking security interest of RBC in the assets of the Company and its subsidiaries. The Company is also subject to a financial covenant on these facilities with a maximum funded debt to EBITDA ratio of 2.50 times, measured quarterly on a rolling four quarter basis.

The following table summarizes proceeds disbursed, interest accrued and principal and interest repayments during the period under these two credit facilities during the period:

Short term debt	Term Loan Facility	Revolving Credit Line Facility	Total Short Term Debt
Loan proceeds disbursed upon acquisition of Oral Science Inc. March 1, 2026 (Note 5)	\$ 6,000,000	\$ 2,000,000	\$ 8,000,000
Accrued interest	16,020	2,937	18,957
Interest payments	(16,020)	(2,937)	(18,957)
Principal payments	(2,000,000)	(2,000,000)	(4,000,000)
Balance, March 31, 2026	\$ 4,000,000	\$ -	\$ 4,000,000

16. Contract Liability

The Company recognizes a contract liability based on its estimate of the amount of consideration it expects to refund to its customers, including consideration payable resulting from coupons and volume rebates. This contract liability is updated at the end of each period for any changes in circumstances.

The table below summarizes changes in the contract liability during the year ended December 31, 2025 and three months ended March 31, 2026:

	Contract Liability (\$)
Balance, December 31, 2024	155,166
Estimated variable consideration	208,713
Settlement of variable consideration	(257,592)
Balance, December 31, 2025	106,287
Estimated variable consideration	51,019
Settlement of variable consideration	(33,877)
Balance, March 31, 2026	123,429

17. Lease Liabilities

The Company leases its head office space in Mississauga, Ontario, Canada. The Company's current office lease commenced on September 1, 2019 and extends to August 31, 2029. The Company has an option to extend this lease beyond the 10-year non-cancellable term for a further term of 5 years. The Company's subsidiary, Oral Science Inc., leases its office and warehouse space in Brossard, Quebec, Canada. This lease extends to March 31, 2028. As per IFRS 16 *Leases*, the Company has recognized right-of-use assets in respect of these leases based on the current lease terms (see Note 13).

The Company has also recognized lease liabilities for its office and warehouse leases based on a weighted average incremental borrowing rate of 5.20%. The carrying amount of the Company's lease liabilities for these leases is summarized in the table below:

	Lease Liability (\$)
Balance, December 31, 2024	1,037,731
Interest expense	49,353
Payments	(245,980)
Balance, December 31, 2025	841,104
Lease liability assumed on acquisition of Oral Science Inc. (Note 5)	475,357
Interest expense	12,659
Payments	(82,087)
Balance, March 31, 2026	1,247,033
Current portion, March 31, 2026	433,838
Long-term portion, March 31, 2026	813,195
Current portion, December 31, 2025	214,360
Long-term portion, December 31, 2025	626,744

The Company's future undiscounted lease payments under these lease agreements are as follows:

Fiscal Year	Lease Payments
2026	448,442
2027	495,534
2028	314,228
2029	168,672
Total	\$ 1,426,876

For the three months ended March 31, 2026, not included in the lease liability, the Company incurred occupancy costs, net of recoveries, related to its office leases of \$47,820 (three months ended March 31, 2025 - \$35,648) which have been included in selling, general and administration expenses in the Company's Consolidated Statements of Comprehensive Income.

18. Share Capital

a. Authorized

The authorized share capital of the Company consists of 100,000,000 common shares without par value and 25,000,000 preferred shares without par value. The holders of the preferred shares as a class shall not be entitled to receive notice of, to attend or to vote at any meeting of the shareholders of the Company.

b. Issued and outstanding common shares

	Number of Issued Common Shares	Number of Treasury Shares	Number of Outstanding Common Shares	Amount
Balance, December 31, 2024	11,489,216	(207,199)	11,282,017	\$ 5,306,450
Cancellation of shares held in Treasury	(5,000)	5,000	-	-
Options exercised (c)	10,731	-	10,731	195,047
Shares repurchased under NCIB for cancellation (d)	(19,500)	-	(19,500)	(9,263)
Shares repurchased for RSU Plan Trust and held in Treasury (e)	-	(40,000)	(40,000)	(453,780)
Release of shares from RSU Plan Trust upon RSU Vesting (g)	-	30,007	30,007	207,306
Balance, December 31, 2025	11,475,447	(212,192)	11,263,255	\$ 5,245,760
Options exercised (c)	4,062	-	4,062	49,986
Shares repurchased under NCIB for cancellation (d)	(100,000)	-	(100,000)	(71,718)
Release of shares from RSU Plan Trust upon RSU Vesting (g)	-	33,365	33,365	19,310
Share consideration issued on acquisition of Oral Science (Note 5)	234,192	-	234,192	3,474,460
Balance, March 31, 2026	11,613,701	(178,827)	11,434,874	\$ 8,717,798

c. Options exercised

During the three months ended March 31, 2026, 4,062 common shares were issued against options exercised (three months ended March 31, 2025 - 5,956 common shares) for total proceeds on exercise of \$25,184 (three months ended March 31, 2025 - \$58,538) and \$24,802 in fair value was transferred from contributed surplus to share capital (three months ended March 31, 2025 - \$56,527).

d. Normal Course Issuer Bid (NCIB)

On December 16, 2024, the Company announced that the TSX Venture Exchange had accepted its renewal of the NCIB, pursuant to which the Company would be permitted to purchase up to 690,000 of its own common shares for cancellation over a further 12-month period commencing on December 19, 2024 and ending on December 18, 2025. Purchases of shares by the Company under the NCIB are made through the facilities of the TSX Venture Exchange or alternative Canadian trading systems at the market price of the shares at the time of acquisition.

During the year ended December 31, 2025, the Company repurchased and cancelled 19,500 of its common shares for an aggregate price of \$214,805 and incurred costs of \$195 related to the repurchase of these shares. The Company's retained earnings were reduced by \$205,737 upon the repurchase of these shares, representing the excess of the aggregate repurchase price over the reduction in share capital of \$9,263.

On December 15, 2025, the Company announced that the TSX Venture Exchange had accepted its renewal of the NCIB, pursuant to which the Company would be permitted to purchase up to 800,000 of its own common shares for cancellation over a further 12-month period commencing on December 19, 2025 and ending on December 18, 2026. Purchases of shares by the Company under the NCIB are made through the facilities of the TSX Venture Exchange or alternative Canadian trading systems at the market price of the shares at the time of acquisition.

During the three months ended March 31, 2026, the Company repurchased and cancelled 100,000 of its common shares for an aggregate price of \$1,400,000 and incurred costs of \$1,000 related

to the repurchase of these shares. The Company's retained earnings were reduced by \$1,329,282 upon the repurchase of these shares, representing the excess of the aggregate repurchase price over the reduction in share capital of \$71,718.

e. RSU Plan Trust

During the year ended December 31, 2025, the Company purchased 40,000 of its common shares pursuant to its RSU Plan (see note 18(g)) for an aggregate purchase price of \$453,780. No such common shares were purchased pursuant to the Company's RSU Plan for the three months ended March 31, 2026.

178,827 treasury shares are held in trust as of March 31, 2026 (December 31, 2025 – 212,192 shares) for future settlement of vested RSUs granted to employees, senior management, and directors of the Company.

f. Preferred Shares

There are nil preferred shares outstanding as of March 31, 2026 (December 31, 2025 – nil).

g. Share-Based Payments

Restricted Share Unit (“RSU”) Plan

The Board adopted a Restricted Share Unit Plan on March 4, 2020, which was approved by shareholders on May 27, 2020 and subsequently approved by the TSX Venture Exchange. The RSU Plan was established as a vehicle by which equity-based incentives may be granted to eligible employees, consultants, directors and officers of the Company to recognize and reward their contributions to the long-term success of the Company including aligning their interests more closely with the interests of the Company's shareholders. The RSU Plan is a fixed plan which reserves for issuance a maximum of 800,000 common shares of the Company.

The table below summarizes the RSUs granted during the three months ended March 31, 2026 and year ended December 31, 2025:

Grant Date	Number of RSUs Granted	Grant Price per Unit	Grantees	Vesting Term	Vesting Dates
01-Mar-26	12,666	\$15.79	Employees (Note 5)	2 Years	01-Mar-28
01-Mar-26	8,682	\$15.79	Management	3 Years	01-Mar-29
24-Mar-26	39,432	\$14.70	Management and Employees	3 Years	23-Mar-29
24-Mar-26	4,790	\$14.70	Directors	3 Years	30-Mar-29 29-Jun-29 28-Sep-29 31-Dec-29
Q1 2026 Total:	65,570	\$ 987,148			
18-Mar-25	50,210	\$11.25	Management and Employees	3 Years	31-Mar-28
18-Mar-25	6,557	\$11.25	Directors	3 Years	31-Mar-28 30-Jun-28 29-Sep-28 29-Dec-28
2025 Total:	56,767	\$ 638,629			

The table below summarizes the RSUs vested during the three months ended March 31, 2026 and year ended December 31, 2025:

Vest Date	Number of RSUs Vested	Value transferred from Contributed Surplus to Share Capital	Number of Common Shares released from RSU Trust	Fair Value of Common Shares released from RSU Trust	Number of Common Shares withheld in RSU Trust	Fair Value of Common Shares withheld in RSU Trust	Net Settlement Amount
31-Mar-26	66,736	\$ 500,520	33,365	\$ 481,167	33,371	\$ 481,210	\$ 19,310
Q1 2026 Totals:	66,736	\$ 500,520	33,365	\$ 481,167	33,371	\$ 481,210	\$ 19,310
31-Mar-25	51,441	\$ 467,599	25,716	\$ 286,733	25,725	\$ 286,834	\$ 180,765
30-Jun-25	3,846	\$ 34,960	1,854	\$ 21,877	1,992	\$ 23,505	\$ 11,455
24-Jul-25	985	\$ 8,953	492	\$ 5,628	493	\$ 5,640	\$ 3,313
30-Sep-25	1,942	\$ 17,653	972	\$ 11,217	970	\$ 11,194	\$ 6,459
31-Dec-25	1,950	\$ 17,726	973	\$ 12,386	977	\$ 12,412	\$ 5,314
2025 Totals:	60,164	\$ 546,891	30,007	\$ 337,841	30,157	\$ 339,585	\$ 207,306

As at March 31, 2026, there were 207,189 RSUs outstanding (December 31, 2025 – 207,628, as shown below):

	March 31, 2026		December 31, 2025	
	Number of RSUs	Weighted average grant price	Number of RSUs	Weighted average grant price
Outstanding, beginning of period	207,628	\$9.02	208,500	\$8.44
Granted	65,570	\$14.87	56,767	\$11.25
Dividend reinvestment	727	\$9.05	3,573	\$8.87
Vested	(66,736)	\$7.50	(60,164)	\$9.04
Forfeited	-		(1,048)	\$9.66
Outstanding, end of period	207,189	\$11.38	207,628	\$9.02

The weighted-average remaining contractual life of the 207,189 RSUs outstanding at March 31, 2026 was 1.86 years (December 31, 2025 – 1.21 years).

During the three months ended March 31, 2026, the Company recorded aggregate share-based payment expense of \$145,949 on the amortization of outstanding RSUs (three months ended March 31, 2025 – \$149,736).

Incentive Stock Option Plan

On March 11, 2014, the Board approved an incentive stock option plan (the “SOP”) which was adopted by the shareholders of the Company on June 13, 2014. The Board approved an amended SOP on March 4, 2020 which was approved by shareholders on May 27, 2020 and re-approved on May 26, 2021, May 17, 2022, May 25, 2023, May 16, 2024, and May 15, 2025. The purpose of the SOP is to assist the Company in attracting, retaining and motivating directors, officers, employees and other persons who provide

ongoing services to the Company and its affiliates and to closely align the personal interests of such participants with those of the Company’s shareholders, by providing them with the opportunity to acquire common shares of the Company, and thereby a proprietary interest in the Company and its subsidiaries, through the exercise of share purchase options.

No options were granted by the Company during the three months ended March 31, 2026 or the three months ended March 31, 2025.

During the three months ended March 31, 2026, the Company recorded \$nil net share-based payment expense (three months ended March 31, 2025 – \$nil) relating to previous option grants to employees, directors, officers and advisors under the SOP, which is included in selling, general and administration expenses in the Consolidated Statements of Comprehensive Income.

As at March 31, 2026 there were 93,614 options outstanding (December 31, 2025 – 104,955), as shown below:

	March 31, 2026		December 31, 2025	
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Outstanding, beginning of period	104,955	\$8.03	124,282	\$8.34
Granted	-	-	-	-
Exercised	(4,062)	\$6.20	(10,731)	\$9.24
Expired	(7,279)	\$6.20	(8,596)	\$10.97
Outstanding, end of period	93,614	\$8.25	104,955	\$8.03

As of March 31, 2026, 93,614 options have vested and are exercisable by the option holders (December 31, 2025 – 104,955). These exercisable options have a weighted average exercise price of \$8.25 (December 31, 2025 – \$8.03).

The weighted-average remaining contractual life of the 93,614 (December 31, 2025 – 104,955) options outstanding is 1.72 years (December 31, 2025 – 1.76 years) and the range of exercise prices for these options is \$7.35 – \$9.94 (December 31, 2025 – \$6.20 – \$9.94).

4,062 options were exercised during the three months ended March 31, 2026 (three months ended March 31, 2025 – 5,956). The weighted average share price on the date of exercise of options exercised during the three months ended March 31, 2026 was \$14.51 (2025 – \$10.84).

Employee Share Purchase Plan

On January 1, 2017, the Company introduced an Employee Share Purchase Plan (“ESPP”). Under the ESPP, eligible BioSyent employees, including certain key management personnel, are

permitted to contribute up to a maximum of 10 per cent of their gross base salary to purchase the Company’s common shares in the open market through the facilities of the TSX Venture Exchange. The contributions are matched by the Company up to a maximum of 2.5 percent of the applicable employee’s gross base salary.

During the three months ended March 31, 2026, the Company recorded share-based payment expense of \$24,232 (three months ended March 31, 2025 – \$38,371) relating to the Company’s contributions to the ESPP for the purchase of common shares on behalf of participating employees. Such share-based payment expense related to the Company’s ESPP contributions has been included in selling, general and administrative expenses in the Consolidated Statements of Comprehensive Income.

h. Dividends

During the three months ended March 31, 2026, the Company paid cash dividends to common shareholders as follows:

Amount per Common Share	Payment Date	Record Date	Aggregate Amount	Amount held in RSU Plan Trust	Net Amount
\$0.055	March 13, 2026	February 27, 2026	\$631,152	\$11,671	\$619,481
TOTAL:			\$631,152	\$11,671	\$619,481

During the year ended December 31, 2025, the Company paid cash dividends to common shareholders as follows:

Amount per Common Share	Payment Date	Record Date	Aggregate Amount	Amount held in RSU Plan Trust	Net Amount
\$0.05	March 14, 2025	February 28, 2025	\$573,421	\$10,110	\$563,311
\$0.05	June 13, 2025	May 30, 2025	\$573,556	\$10,824	\$562,732
\$0.05	September 15, 2025	August 29, 2025	\$573,772	\$10,707	\$563,065
\$0.05	December 15, 2025	November 28, 2025	\$573,772	\$10,658	\$563,114
TOTAL:			\$2,294,521	\$42,299	\$2,252,222

19. Expenses by Nature

The expenses on the Consolidated Statements of Comprehensive Income have been grouped by function to focus reader attention on the macro movements in cost from period to period while giving the reader an option to see the detail of expenses according to their nature, which are included below:

	Three months ended March 31,	
	2026	2025
Cost of goods sold (Note 9)	\$ 3,739,946	\$ 2,641,768
Selling and marketing	\$ 4,256,371	\$ 3,464,196
Advertising, Promotion and Selling Costs	1,712,143	1,570,958
Employee Costs	1,993,521	1,614,298
Logistics, Quality Control & Regulatory	520,483	251,766
Share-based Payments (Note 18)	30,224	27,174
General and administration	\$ 2,761,740	\$ 1,882,532
Employee Costs	1,068,369	778,940
Amortization - Intangible Assets (Note 14)	394,849	144,276
Corporate Expenses	324,159	338,344
Transaction costs (Note 5)	273,030	-
Information Technology	229,916	123,181
Share-based Payments (Note 18)	143,957	160,933
Professional Fees	126,156	104,880
Depreciation - Property and Equipment (Note 13)	94,112	66,907
Insurance	63,574	62,770
Net Foreign Exchange (Gains) Losses	24,506	(41,868)
New business development costs	18,451	54,789
Expected Credit Losses	661	-
Research	-	89,380
Finance costs	\$ 31,616	\$ 13,103
Interest expense - short term debt (Note 15)	18,957	-
Interest expense - lease liability (Note 17)	12,659	13,103
Finance income	\$ (166,792)	\$ (179,010)
Interest Income	(166,792)	(179,010)

With the acquisition and consolidation of Oral Science Inc., certain expense amounts in the chart above for the period ended March 31, 2025 have been reclassified to conform with the classification of such amounts by nature for the current period ended March 31, 2026.

20. Earnings per Share

The following table reconciles the numerator and denominator for the calculation of basic and diluted earnings per share:

	Three months ended March 31,	
	2026	2025
Numerator		
Net income attributable to common shareholders	2,344,819	\$ 2,319,933
Denominator		
Basic		
Weighted average number of shares outstanding	11,336,104	11,269,162
Effect of dilutive securities	261,498	246,711
Weighted average number of shares outstanding	11,597,602	11,515,873
Basic earnings per share	\$ 0.207	\$ 0.206
Diluted earnings per share	\$ 0.202	\$ 0.201

21. Contingencies

Litigations

From time to time, the Company may be exposed to claims and legal actions in the normal course of business. As at March 31, 2026, the Company was not aware of any litigation or threatened claims either outstanding or pending.

Inofolic® License and Supply Agreement

Under the terms of the 2020 License and Supply Agreement for Inofolic® (see Note 14), the Company is required to make certain royalty payments to the Licensor equal to 6.00% of the estimated

net selling price of the product, which are included in the per unit purchase price of product purchased by the Company from the Licensor. For the three months ended March 31, 2026 and 2025, such fees, which are not material in amount, have been expensed and included in the Company's Consolidated Statements of Comprehensive Income.

22. Commitments

Office Leases

The Company's current office and warehouse lease agreements extend to August 31, 2029 and March 31, 2028 (see Note 17).

The Company's undiscounted minimum future rental payments and estimated occupancy costs (including certain operating costs and realty taxes) for the current and next three fiscal years under these two lease agreements are approximately as follows:

Fiscal Year	Annual Rent and Occupancy Costs
2026	\$ 537,463
2027	\$ 763,710
2028	\$ 388,633
2029	\$ 259,089
Total	\$ 1,948,895

Purchase Commitments

In the normal course of business, the Company has minimum purchase commitments with certain suppliers.

23. Related Party Transactions

Key Management Personnel Compensation

Key management personnel are those persons having authority and responsibility for planning, directing and controlling the activities of the Company and/or its subsidiaries, directly or indirectly.

The table below summarizes compensation for key management personnel of the Company for the three months ended March 31, 2026 and 2025:

	Three months ended March 31,	
	2026	2025
Number of Key Management Personnel	7	5
Salary, Benefits, and Bonus	\$417,429	\$324,113
Share-Based Payments	\$93,730	\$74,016

During the three months ended March 31, 2025, the Company recorded share-based payment expense of \$93,730 (three months ended March 31, 2025 - \$74,016) related to the amortization of RSUs granted to key management under the Company's RSU Plan as well as the Company's contributions to the ESPP for the purchase of common shares on behalf of participating key management personnel.

As at March 31, 2026, there were loans receivable under the MSLP from key management personnel of \$72,375 (March 31, 2025 - \$96,485). MSLP loan repayments of \$17,741 were received from key management personnel during the three months ended March 31, 2026 (three months ended March 31, 2025 - \$55,425). Interest

accrued on these MSLP loans during the three months ended March 31, 2026 totalled \$943 (three months ended March 31, 2025 - \$1,828).

Transactions with Directors

During the three months ended March 31, 2026, the Company paid cash fees to its directors in the amount of \$49,396 (three months ended March 31, 2025 - \$37,866) and recorded share-based payments expense for accounting purposes of \$18,659 (three months ended March 31, 2025 - \$20,958) related to the amortization of RSUs under the Company's RSU Plan.

24. Capital Disclosures

For capital management purposes, the Company defines capital as its shareholders' equity that includes share capital, contributed surplus, cumulative translation adjustment and retained earnings.

The amounts included in the Company's capital for the relevant years are as follows:

March 31, 2026	\$44,993,439
December 31, 2025	\$41,465,506

The Company's principal objectives in managing capital are:

- to ensure that it will continue to operate as a going concern;
- to be flexible in order to take advantage of contract and growth opportunities that are expected to provide satisfactory returns to its shareholders;

- to maintain a strong capital base in order to maintain customers, investors, creditors and market confidence; and
- to provide an adequate rate of return to its shareholders.

The Company manages and adjusts its capital structure in light of changes in economic conditions.

In order to maintain or adjust its capital structure, the Company may issue debt or new shares. Financing decisions are generally made on a specific transaction basis and depend on such things as the Company's needs, capital markets and economic conditions at the time of the transaction. Management reviews its capital management approach on an ongoing basis and believes that this approach is reasonable, given the size of the Company.

There were no changes in the Company's approach to capital management during the period.

25. Credit Facilities

At March 31, 2026, the Company had credit facilities available with Royal Bank of Canada including a term loan facility and a revolving demand credit facility of up to \$12,000,000 (see Note 15) a foreign exchange facility, and credit card facilities totalling \$200,000.

At March 31, 2026, \$4,000,000 remained outstanding under the term loan facility and \$nil was outstanding under the revolving demand credit facility.

26. Taxes

The Company computes an income tax provision in each of the jurisdictions in which it operates. Actual amounts of income tax expense only become final upon filing and acceptance of the tax return by the relevant authorities, which occur subsequent to the issuance of the financial statements.

Additionally, estimation of income taxes includes evaluating the recoverability of deferred tax assets based on an assessment of the ability to use the underlying future tax deductions before they expire against future taxable income.

The assessment is based upon existing tax laws and estimates of future taxable income. To the extent estimates differ from the final tax return, earnings would be affected in a subsequent period. The operations are subject to income tax rates of 26.5% (2025 - 26.5%) in the Canadian jurisdiction, 22.1% (2025 - 22.1%) in the U.S. jurisdiction, and 9.0% (2025 - 9.0%) in the Barbados jurisdiction.

27. Segment Reporting

A segment is a component of the Company:

- i. that engages in business activities from which it may earn revenue and incur expenses;
- ii. whose operating results are reviewed by the board of directors; and
- iii. for which discrete financial information available.

Description of the types of products and services from which each reportable segment derives its revenues

The Company has two reportable segments: The Pharmaceutical Segment and the Oral Health Segment. The Pharmaceutical Segment sources and markets pharmaceutical products to Canadian consumers and healthcare professionals which are distributed by wholesalers through retail pharmacies. The Pharmaceutical Segment also supplies pharmaceutical products to certain markets outside of Canada which are marketed and distributed by distributors in these local markets. The Oral Health Segment sources, markets and distributes dental hygiene and oral health products to Canadian dental clinics, pharmacies and through online sales to consumers, while seeking opportunities for international distribution of these

products. The Other segment includes the Company's legacy insecticides business which markets and distributes biologically and health friendly non-chemical insecticides in North America and which is not a material segment.

Measurement of operating segment profit or loss, assets and liabilities

The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies. The Company evaluates operating segment performance on the basis of contribution profit; that is, net income before general and administrative expenses, finance costs, finance income, and taxes.

Factors that management used to identify the entity's reportable segments

The Company's reportable segments are strategic business units that offer different products and services. These segments are managed individually because each business operates in a different environment and each requires a different marketing strategy. The Oral Health Segment was acquired by the Company in March 2026 as an individual business unit and its management was retained.

Information about reportable segment profit and loss, assets and liabilities

Three months ended March 31, 2026	Pharmaceutical	Oral Health	Other	Totals
Revenues from external customers	10,803,107	2,984,973	120,102	13,908,182
Reportable segment operating profit (loss)	4,973,864	854,428	83,573	5,911,865
Reportable segment assets	17,842,120	11,603,273	385,495	29,830,888
Additions to reportable segment non-current assets	-	-	-	-
Reportable segment liabilities	5,113,110	2,587,647	319,693	8,020,450

Three months ended March 31, 2025	Pharmaceutical	Oral Health	Other	Totals
Revenues from external customers	10,694,868	-	284,092	10,978,960
Reportable segment operating profit (loss)	4,855,536	-	179,846	5,035,382
Reportable segment assets	32,634,132	-	123,448	32,757,580
Additions to reportable segment non-current assets	-	-	-	-
Reportable segment liabilities	3,895,913	-	300,443	4,196,356

Reconciliations for reportable segment revenues, profit, assets and liabilities

Revenues	Three months ended March 31, 2026
Total revenue from reportable segments	13,908,182

Profit	Three months ended March 31, 2026
Total profit for reportable segments	5,911,865
General and administrative expenses	(2,761,740)
Interest expense	(31,616)
Interest income	166,792
Net income before taxes	3,285,301

Assets	March 31, 2026
Total assets for reportable segments	29,830,888
Long term investments	3,293,957
Property and equipment	1,708,020
Intangible assets	21,828,234
Goodwill	3,750,000
Other corporate assets	2,080,811
Total assets	62,491,910

Liabilities	March 31, 2026
Total liabilities for reportable segments	8,020,450
Short term debt	4,000,000
Contingent consideration	1,816,894
Office lease liabilities	1,247,033
Other liabilities	2,414,094
Total liabilities	17,498,471

Geographical information- for the three months ended March 31, 2026	Revenues	Non-current assets
Canada	13,041,048	31,076,009
Other countries	867,134	92,743
Total	13,908,182	31,168,752

28. Subsequent Event

Dividend Declaration

On May 14, 2026, the Company's Board of Directors declared a dividend of \$0.055 per common share to shareholders of record on May 29, 2026 payable on June 15, 2026.

Corporate Information

Registered Office

Suite 402
2476 Argentia Road
Mississauga, Ontario, Canada L5N 6M1
Telephone 905.206.0013
Facsimile 905.206.1413
Email info@biosyent.com
Website www.biosyent.com

Board of Directors

Joseph Arcuri

Ontario, Canada

Sara Elford

British Columbia, Canada

René C. Goehrum (Chair)

Ontario, Canada

Prakash Gowd

Ontario, Canada

Peter D. Lockhard (Lead Director)

Ontario, Canada

Stephen Wilton

Ontario, Canada

Officers

René C. Goehrum

President and
Chief Executive Officer

Robert J. March

Vice-President and
Chief Financial Officer

Registrar and Transfer Agent

Computershare Trust Company Canada

100 University Avenue,
Toronto, Ontario, M5J 2Y1
Canada

Auditor

MNP LLP

Toronto, Ontario, Canada

Solicitors

Wildeboer Dellelce LLP

Toronto, Ontario, Canada

Caravel Law

Toronto, Ontario, Canada

Harridyal Sodha & Associates

St. Michael, Barbados

Banks

Royal Bank of Canada

Toronto, Ontario, Canada

Canadian Imperial Bank of Commerce

Toronto, Ontario, Canada

City National Bank

Los Angeles, California, USA

Stock Listing

TSX Venture Exchange

Trading symbol: RX